Abstract
Psoriatic arthritis (PsA) may affect different joints, including the spine. The prevalence of spinal involvement is variable depending on the definition and a subset of patients have been identified in cohorts that do not have clinical features of axial disease and yet have imaging findings. Still, there is not a consensus on how and when to screen axial disease. In this study, we aimed to investigate factors associated with being underdiagnosed for axial psoriatic arthritis (axPsA) and its impacts on outcomes. Disease features and outcomes of axPsA according to the physician (n = 415) were compared with patients with imaging findings only (sacroiliitis fulfilling the modified New York criteria, n = 112), using data from a real-life PsA registry. Patients with imaging findings only were more frequently women (83/220 (37.7%) vs 29/122 (23.8%); p = 0.008). This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA. Patient-reported outcomes were similar in both groups. PsA patients, especially women with more severe peripheral disease, have a higher risk of being underdiagnosed for axPsA. The severity of peripheral symptoms may be a risk factor to mask the spinal features of PsA.
References
Gladman DD (2015) Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin N Am 41:569–579. https://doi.org/10.1016/j.rdc.2015.07.003
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78. https://doi.org/10.1016/0049-0172(73)90035-8
Hanly JG, Russell ML, Gladman DD (1988) Psoriatic spondyloarthropathy: a long term prospective study. Ann Rheum Dis 47:386–393. https://doi.org/10.1136/ard.47.5.386
Battistone MJ, Manaster BJ, Reda DJ, Clegg DO (1999) The prevalence of sacroilitis in psoriatic arthritis: new perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study. Skeletal Radiol 28:196–201. https://doi.org/10.1007/s002560050500
Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, Jobling A, Shaddick G, Bi J, Winchester R, Giles JT, McHugh NJ (2017) Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 76:701–707. https://doi.org/10.1136/annrheumdis-2016-209853
Queiro R, Belzunegui J, Gonzalez C et al (2002) Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Clin Rheumatol 21:10–13. https://doi.org/10.1007/s100670200003
Gladman DD (1998) Psoriatic arthritis. Rheum Dis Clin N Am 24:829–844. https://doi.org/10.1016/S0889-857X(05)70044-2
Gladman DD (1994) Natural history of psoriatic arthritis. Baillie’res Clin Rheumatol 8:379–394. https://doi.org/10.1016/S0950-3579(94)80024-3
Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Ståhle M (2008) Clinical and genetic registries in psoriatic disease. J Rheumatol 35:1458–1463
Kalyoncu U, Bayindir O, Ferhat Oksuz M et al (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56:279–286. https://doi.org/10.1093/rheumatology/kew375
Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368. https://doi.org/10.1002/art.1780270401
Aydin SZ, Kasapoglu Gunal E, Kurum E, Akar S, Mungan HE, Alibaz-Oner F, Lambert RG, Atagunduz P, Marzo Ortega H, McGonagle D, Maksymowych WP (2017a) Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis. Rheumatology (Oxford) 56:2162–2169. https://doi.org/10.1093/rheumatology/kex321
Aydin SZ, Kilic L, Kucuksahin O, Ureyen SB, Kalyoncu U (2017b) Performances of inflammatory back pain criteria in axial psoriatic arthritis. Rheumatology (Oxford) 56:2031–2032. https://doi.org/10.1093/rheumatology/kex307
Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O’Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071. https://doi.org/10.1002/art.39573
Ramiro S, Smolen JS, Landewe R et al (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75:490–498. https://doi.org/10.1136/annrheumdis-2015-208466
Acknowledgments
We would like to thank the following collaborators for their participation: Adem Kucuk, Emel Gonullu, Emine Duygu Ersozlu Bozkir, Funda Erbasan, Gozde Yildirim Cetin, Senol Kobak, Serpil Ergullu Esmen, Servet Akar, Seval Pehlevan, Soner Senel, Tuncay Duruoz, Kenan Aksu, Yasemin Kabasakal, Timucin Kasifoglu.
We would also like to thank Drs Laure Gossec and Helena Marzo-Ortega for criticizing and helping to improve our dataset and analyzing for this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Sibel Aydin has received honoraria from Abbvie, Novartis, Pfizer, UCB, and Sanofi.
Rights and permissions
About this article
Cite this article
Aydin, S.Z., Kucuksahin, O., Kilic, L. et al. Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. Clin Rheumatol 37, 3443–3448 (2018). https://doi.org/10.1007/s10067-018-4173-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4173-4